X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-09-15 | DICE | Dice Therapeutics, Inc. | Scopa James Paul | Dir | P - Purchase | $17.00 | +6,000 | 55,841 | +12% | +$102,000 | |||||
| D | 2021-09-14 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | 10% | P - Purchase | $2.70 | +5,000 | 31,870,388 | 0% | +$13,492 | |||||
2021-09-14 | INDP | Indaptus Therapeutics, Inc. | Meckler Jeffrey A | CEO, Dir | P - Purchase | $7.00 | +12,000 | 14,460 | +488% | +$84,000 | ||||||
| M | 2021-09-14 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale | $25.04 | -1,388 | 228,772 | -1% | -$34,760 | |||||
| M | 2021-09-14 | ORIC | Oric Pharmaceuticals, Inc. | Chacko Jacob | Pres, CEO | S - Sale | $25.05 | -8,156 | 2,652 | -75% | -$204,335 | |||||
| M | 2021-09-14 | BGNE | Beigene, Ltd. | Oyler John | CEO | S - Sale | $82.04 | -411,838 | 49,551,731 | -1% | -$33,788,320 | |||||
| M | 2021-09-14 | RAPT | Rapt Therapeutics, Inc. | Column Group Ii, LP | 10% | S - Sale | $37.01 | -181,211 | 3,146,989 | -5% | -$6,707,218 | |||||
| D | 2021-09-14 | AUPH | Aurinia Pharmaceuticals Inc. | Martin Michael Robert | Chief Business Officer | S - Sale+OE | $21.78 | -44,000 | 397,722 | -10% | -$958,220 | |||||
| D | 2021-09-15 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | S - Sale+OE | $61.13 | -1,394 | 0 | -100% | -$85,215 | |||||
| M | 2021-09-14 | MYOV | Myovant Sciences Ltd. | Sumitomo Chemical Co., Ltd. | 10% | P - Purchase | $22.03 | +161,164 | 49,628,522 | 0% | +$3,551,175 | |||||
| D | 2021-09-16 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $204.08 | -6,000 | 36,369 | -14% | -$1,224,467 | |||||
| D | 2021-09-14 | OPNT | Opiant Pharmaceuticals, Inc. | Thomas Thomas T. | Dir | S - Sale+OE | $19.37 | -1,571 | 8,107 | -16% | -$30,431 | |||||
| D | 2021-09-14 | GBIO | Generation Bio Co. | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $28.07 | -4,500 | 198,154 | -2% | -$126,315 | |||||
2021-09-16 | OPNT | Opiant Pharmaceuticals, Inc. | Crystal Roger | CEO, 10% | P - Purchase | $23.44 | +100 | 5,100 | +2% | +$2,344 | ||||||
2021-09-14 | CMRX | Chimerix Inc | Cantex Pharmaceuticals, Inc. | 10% | S - Sale | $5.75 | -6,500,000 | 3,500,000 | -65% | -$37,375,000 | ||||||
| D | 2021-09-15 | QURE | Uniqure N.V. | Kuta Alexander Edward III | EVP, Operations | S - Sale+OE | $36.32 | -6,000 | 68,871 | -8% | -$217,920 | |||||
2021-09-16 | TFFP | Tff Pharmaceuticals, Inc. | Mattes Glenn R. | Pres, CEO | P - Purchase | $7.10 | +10,000 | 27,000 | +59% | +$71,000 | ||||||
2021-09-16 | TFFP | Tff Pharmaceuticals, Inc. | Coleman Kirk Allen | CFO, Secretary, Treasurer | P - Purchase | $7.30 | +1,000 | 2,000 | +100% | +$7,300 | ||||||
2021-09-14 | NBRV | Nabriva Therapeutics Plc | Schroeder Theodore R | CEO | P - Purchase | $1.13 | +50,000 | 226,875 | +28% | +$56,500 | ||||||
| M | 2021-09-13 | SPRO | Spero Therapeutics, Inc. | Aquilo Capital Management, LLC | 10% | P - Purchase | $18.56 | +46,366 | 4,429,145 | +1% | +$860,547 | |||||
| D | 2021-09-15 | CYRX | Cryoport, Inc. | Berman Richard J | Dir | S - Sale+OE | $64.00 | -25,000 | 100,000 | -20% | -$1,599,875 | |||||
| D | 2021-09-13 | ANNX | Annexon, Inc. | Yednock Ted | EVP, Chief Scientific Officer | S - Sale+OE | $20.00 | -16,190 | 0 | -100% | -$323,860 | |||||
| D | 2021-09-13 | ANNX | Annexon, Inc. | Lew Jennifer | EVP, CFO | S - Sale+OE | $20.01 | -3,500 | 2,000 | -64% | -$70,034 | |||||
2021-09-13 | BGNE | Beigene, Ltd. | Huang Jane | CMO, Hematology | S - Sale | $358.14 | -12,901 | 145,235 | -8% | -$4,620,390 | ||||||
| M | 2021-09-13 | CORT | Corcept Therapeutics Inc | Robb Gary Charles | Chief Business Officer | S - Sale | $20.54 | -55,000 | 101,540 | -35% | -$1,129,923 | |||||
2021-09-13 | IMRX | Immuneering Corp | Feinberg Peter | Dir | P - Purchase | $21.50 | +6,099 | 984,647 | +1% | +$131,114 | ||||||
2021-09-15 | DMAC | Diamedica Therapeutics Inc. | Alcorn Harry W Jr | SVP, Clinical Operations | P - Purchase | $3.80 | +15,000 | 43,981 | +52% | +$56,960 | ||||||
2021-09-14 | ANGN | Angion Biomedica Corp. | Rhodes Jennifer J | See Remarks | S - Sale | $10.64 | -430 | 31,713 | -1% | -$4,575 | ||||||
| DM | 2021-09-13 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | Pres, COO | S - Sale+OE | $19.12 | -61,000 | 17,659 | -78% | -$1,166,033 | |||||
| D | 2021-09-13 | BPMC | Blueprint Medicines Corp | Hurley Ariel | Principal Accounting Officer | S - Sale+OE | $100.00 | -600 | 10,097 | -6% | -$60,000 | |||||
| D | 2021-09-13 | BPMC | Blueprint Medicines Corp | Haviland Kate | COO | S - Sale+OE | $99.94 | -1,000 | 53,948 | -2% | -$99,936 | |||||
2021-09-15 | ATXI | Avenue Therapeutics, Inc. | Vazzano Joseph Walter | CFO | S - Sale | $1.62 | -7,160 | 65,252 | -10% | -$11,599 | ||||||
| DM | 2021-09-13 | REGN | Regeneron Pharmaceuticals, Inc. | Zoghbi Huda Y | Dir | S - Sale+OE | $650.00 | -1,000 | 891 | -53% | -$650,002 | |||||
2021-09-14 | OPNT | Opiant Pharmaceuticals, Inc. | O'Toole David D | CFO | P - Purchase | $19.12 | +200 | 24,015 | +1% | +$3,824 | ||||||
2021-09-13 | OPNT | Opiant Pharmaceuticals, Inc. | Collard Craig A | Dir | P - Purchase | $18.13 | +2,500 | 17,283 | +17% | +$45,325 | ||||||
2021-09-14 | NMTR | 9 Meters Biopharma, Inc. | Sitar Edward J | CFO | P - Purchase | $1.22 | +15,000 | 194,338 | +8% | +$18,300 | ||||||
2021-09-13 | OCUP | Ocuphire Pharma, Inc. | Pepose Jay | Dir | P - Purchase | $4.75 | +12,631 | 14,744 | +598% | +$59,997 | ||||||
2021-09-14 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $3.46 | +100,000 | 226,367,822 | 0% | +$346,443 | ||||||
| M | 2021-09-13 | NGM | Ngm Biopharmaceuticals Inc | Chen Jin-Long | Chief Scientific Officer | S - Sale | $25.84 | -30,000 | 929,449 | -3% | -$775,306 | |||||
| D | 2021-09-13 | HRMY | Harmony Biosciences Holdings, Inc. | Jacobs John C | Pres, CEO | S - Sale+OE | $35.93 | -25,000 | 0 | -100% | -$898,263 | |||||
| DM | 2021-09-10 | AUPH | Aurinia Pharmaceuticals Inc. | Martin Michael Robert | Chief Business Officer | S - Sale+OE | $20.89 | -115,000 | 353,722 | -25% | -$2,402,217 | |||||
2021-09-10 | PGEN | Precigen, Inc. | Ares Trading S.A. | 10% | S - Sale | $6.29 | -4,584 | 21,098,706 | 0% | -$28,814 | ||||||
| M | 2021-09-10 | RAPT | Rapt Therapeutics, Inc. | Column Group Ii, LP | 10% | S - Sale | $35.22 | -36,055 | 3,183,459 | -1% | -$1,269,950 | |||||
2021-09-13 | ARWR | Arrowhead Pharmaceuticals, Inc. | Olukotun Adeoye Y | Dir | S - Sale | $63.76 | -5,000 | 9,000 | -36% | -$318,800 | ||||||
| M | 2021-09-10 | AUPH | Aurinia Pharmaceuticals Inc. | Huizinga Robert Bindert | EVP of Research | S - Sale | $21.15 | -32,500 | 106,092 | -23% | -$687,325 | |||||
| D | 2021-09-10 | AUPH | Aurinia Pharmaceuticals Inc. | Solomons Neil | Chief Medical Officer | S - Sale+OE | $19.84 | -150,000 | 137,299 | -52% | -$2,976,000 | |||||
| D | 2021-09-14 | ATNX | Athenex, Inc. | Wu Jinn | Dir | P - Purchase | $3.22 | +50,000 | 403,208 | +14% | +$161,000 | |||||
| D | 2021-09-13 | SDGR | Schrodinger, Inc. | Abel Robert Lorne | See Remarks | S - Sale+OE | $61.75 | -15,602 | 0 | -100% | -$963,435 | |||||
2021-09-13 | IMRX | Immuneering Corp | Zeskind Benjamin J. | Pres, CEO, 10% | P - Purchase | $22.87 | +2,083 | 3,147,279 | 0% | +$47,632 | ||||||
| M | 2021-09-13 | APLT | Applied Therapeutics Inc. | Shendelman Shoshana | Pres, CEO, 10% | P - Purchase | $14.50 | +10,001 | 4,694,777 | 0% | +$145,038 | |||||
2021-09-10 | TCDA | Tricida, Inc. | Coufal Sandra I | Dir, 10% | S - Sale | $4.23 | -5,000 | 6,572,265 | 0% | -$21,150 | ||||||
| D | 2021-09-10 | GBIO | Generation Bio Co. | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $25.97 | -3,000 | 198,154 | -1% | -$77,910 | |||||
2021-09-14 | OPNT | Opiant Pharmaceuticals, Inc. | Gorman Brian | General Counsel | P - Purchase | $19.04 | +1,312 | 21,586 | +6% | +$24,980 | ||||||
| M | 2021-09-10 | ORIC | Oric Pharmaceuticals, Inc. | Chacko Jacob | Pres, CEO | S - Sale | $25.05 | -5,743 | 10,808 | -35% | -$143,872 | |||||
2021-09-14 | CLRB | Cellectar Biosciences, Inc. | Swirsky Douglas J | Dir | P - Purchase | $1.04 | +25,000 | 25,000 | New | +$26,000 | ||||||
2021-09-14 | TBIO | Translate Bio, Inc. | Sanofi | 10% | P - Purchase | $38.00 | +71,983,597 | 75,668,031 | >999% | +$2,147,483,647 | ||||||
2021-09-13 | IMNM | Immunome Inc. | Rapp Michael | Dir | P - Purchase | $19.96 | +25,962 | 1,008,608 | +3% | +$518,202 | ||||||
| M | 2021-09-09 | PMVP | Pmv Pharmaceuticals, Inc. | Schroeder Thilo | Dir | S - Sale | $30.41 | -70,828 | 1,124,974 | -6% | -$2,154,007 | |||||
| D | 2021-09-10 | OLMA | Olema Pharmaceuticals, Inc. | Horn Kinney | Chief Business Officer | S - Sale+OE | $29.38 | -5,251 | 1,790 | -75% | -$154,274 | |||||
2021-09-10 | ALXO | Alx Oncology Holdings Inc | Randolph Sophia | Chief Medical Officer | S - Sale | $77.66 | -7,387 | 156,815 | -4% | -$573,670 | ||||||
| DM | 2021-09-09 | MORF | Morphic Holding, Inc. | Rogers Bruce | Chief Scientific Officer | S - Sale+OE | $62.00 | -40,000 | 89,905 | -31% | -$2,480,045 | |||||
2021-09-09 | EMMA | Emmaus Life Sciences, Inc. | Niihara Yutaka | COB, CEO, 10% | P - Purchase | $1.67 | +2,500 | 11,028,859 | 0% | +$4,175 | ||||||
2021-09-13 | TYME | Tyme Technologies, Inc. | Demurjian Michael | 10% | S - Sale | $1.04 | -20,000 | 24,258,546 | 0% | -$20,800 | ||||||
2021-09-13 | EYEN | Eyenovia, Inc. | Rowe Michael M | COO | P - Purchase | $4.40 | +1,500 | 4,300 | +54% | +$6,600 | ||||||
| D | 2021-09-09 | VNDA | Vanda Pharmaceuticals Inc. | Mitchell Stephen Ray | Dir | S - Sale+OE | $16.74 | -19,109 | 9,215 | -67% | -$319,976 | |||||
| D | 2021-09-09 | MYOV | Myovant Sciences Ltd. | Curran Terrie | Dir | S - Sale+OE | $25.58 | -4,850 | 0 | -100% | -$124,063 | |||||
2021-09-10 | OPNT | Opiant Pharmaceuticals, Inc. | Collard Craig A | Dir | P - Purchase | $18.18 | +9,577 | 13,577 | +239% | +$174,110 | ||||||
| D | 2021-09-10 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $35.93 | -2,000 | 1,286 | -61% | -$71,860 | |||||
| D | 2021-09-10 | REGN | Regeneron Pharmaceuticals, Inc. | Goldstein Joseph L | Dir | S - Sale+OE | $650.00 | -2,479 | 5,891 | -30% | -$1,611,350 | |||||
| D | 2021-09-10 | RAPT | Rapt Therapeutics, Inc. | Brockstedt Dirk G. | Chief Scientific Officer | S - Sale+OE | $35.78 | -2,648 | 19,812 | -12% | -$94,745 | |||||
| M | 2021-09-09 | IMNM | Immunome Inc. | Rapp Michael | Dir | P - Purchase | $18.07 | +45,950 | 982,646 | +5% | +$830,449 | |||||
2021-09-02 | BAMM | Body & Mind Inc. | Australis Capital Inc | 10% | S - Sale | $0.24 | -5,900,000 | 8,206,549 | -42% | -$1,398,890 | ||||||
2021-09-09 | GBT | Global Blood Therapeutics, Inc. | Morrison Scott W | Dir | S - Sale | $30.21 | -4,800 | 3,037 | -61% | -$145,003 | ||||||
| M | 2021-09-08 | EMMA | Emmaus Life Sciences, Inc. | Lee Willis C | Vice COB, COO | P - Purchase | $1.71 | +4,000 | 368,335 | +1% | +$6,840 | |||||
| D | 2021-09-08 | ABT | Abbott Laboratories | Pederson Michael J | SVP | S - Sale+OE | $129.05 | -23,008 | 62,646 | -27% | -$2,969,173 | |||||
| DM | 2021-09-08 | NKTR | Nektar Therapeutics | Chess Robert | Dir | S - Sale+OE | $16.01 | -18,279 | 280,573 | -6% | -$292,670 | |||||
| M | 2021-09-08 | PGEN | Precigen, Inc. | Ares Trading S.A. | 10% | S - Sale | $6.31 | -90,621 | 21,103,290 | 0% | -$571,402 | |||||
| A | 2021-08-19 | HCWB | Hcw Biologics Inc. | Byam Rebecca | CFO | P - Purchase | $4.40 | +10,000 | 62,000 | +19% | +$43,979 | |||||
| M | 2021-08-02 | CPIX | Cumberland Pharmaceuticals Inc | Kazimi A J | COB, CEO, 10% | P - Purchase | $2.98 | +315 | 5,769,144 | 0% | +$938 | |||||
| M | 2021-07-01 | CPIX | Cumberland Pharmaceuticals Inc | Kazimi A J | COB, CEO, 10% | P - Purchase | $3.27 | +315 | 5,768,829 | 0% | +$1,029 | |||||
2021-09-09 | SPRO | Spero Therapeutics, Inc. | Aquilo Capital Management, LLC | 10% | P - Purchase | $18.50 | +24,749 | 4,382,779 | +1% | +$457,792 | ||||||
| M | 2021-05-28 | CPIX | Cumberland Pharmaceuticals Inc | Kazimi A J | COB, CEO, 10% | P - Purchase | $3.04 | +345 | 5,768,514 | 0% | +$1,049 | |||||
| M | 2021-04-16 | CPIX | Cumberland Pharmaceuticals Inc | Kazimi A J | COB, CEO, 10% | P - Purchase | $2.88 | +450 | 5,768,169 | 0% | +$1,295 | |||||
| M | 2021-08-02 | CPIX | Cumberland Pharmaceuticals Inc | Young Caroline | Dir | P - Purchase | $2.98 | +315 | 13,358 | +2% | +$938 | |||||
| M | 2021-07-01 | CPIX | Cumberland Pharmaceuticals Inc | Young Caroline | Dir | P - Purchase | $3.27 | +315 | 13,043 | +2% | +$1,029 | |||||
| M | 2021-05-28 | CPIX | Cumberland Pharmaceuticals Inc | Young Caroline | Dir | P - Purchase | $3.04 | +345 | 12,728 | +3% | +$1,049 | |||||
| M | 2021-04-16 | CPIX | Cumberland Pharmaceuticals Inc | Young Caroline | Dir | P - Purchase | $2.88 | +450 | 12,383 | +4% | +$1,295 | |||||
| M | 2021-08-02 | CPIX | Cumberland Pharmaceuticals Inc | Galante Joseph C | Dir | P - Purchase | $2.98 | +2,982 | 37,813 | +9% | +$8,881 | |||||
| M | 2021-08-02 | CPIX | Cumberland Pharmaceuticals Inc | Jones James | Dir | P - Purchase | $2.98 | +882 | 16,296 | +6% | +$2,627 | |||||
| D | 2021-09-09 | PRTA | Prothena Corp Public Ltd Co | Karp Carol D. | Chief Regulatory Officer | S - Sale+OE | $71.98 | -10,000 | 0 | -100% | -$719,847 | |||||
| M | 2021-08-02 | CPIX | Cumberland Pharmaceuticals Inc | Krogulski Kenneth | Dir | P - Purchase | $2.98 | +1,785 | 175,570 | +1% | +$5,316 | |||||
| M | 2021-08-02 | CPIX | Cumberland Pharmaceuticals Inc | Cearnal Martin E | SVP, Chief Commercial Officer | P - Purchase | $2.98 | +2,205 | 169,464 | +1% | +$6,567 | |||||
| M | 2021-09-08 | MYOV | Myovant Sciences Ltd. | Sumitomo Chemical Co., Ltd. | 10% | P - Purchase | $25.60 | +58,902 | 49,354,180 | 0% | +$1,507,811 | |||||
| DM | 2021-09-08 | KRTX | Karuna Therapeutics, Inc. | Ignelzi Troy A. | CFO | S - Sale+OE | $117.39 | -10,000 | 18,000 | -36% | -$1,173,846 | |||||
2021-09-08 | LUMO | Lumos Pharma, Inc. | McKew John C. | Chief Scientific Officer | S - Sale | $11.30 | -2,214 | 31,012 | -7% | -$25,018 | ||||||
2021-09-09 | ARWR | Arrowhead Pharmaceuticals, Inc. | Given Douglas B | Dir | S - Sale | $65.24 | -5,000 | 136,243 | -4% | -$326,200 | ||||||
| D | 2021-09-09 | ZLAB | Zai Lab Ltd | Reinhart Harald | Chief Medical Officer | S - Sale+OE | $141.36 | -10,000 | 0 | -100% | -$1,413,621 | |||||
| D | 2021-09-09 | PMVP | Pmv Pharmaceuticals, Inc. | Alland Leila | Chief Medical Officer | S - Sale+OE | $30.25 | -100 | 0 | -100% | -$3,025 | |||||
2021-09-08 | JAZZ | Jazz Pharmaceuticals Plc | Larkin Finbar | SVP, Technical Operations | S - Sale | $134.51 | -63 | 16,579 | 0% | -$8,474 | ||||||
| D | 2021-09-07 | HRMY | Harmony Biosciences Holdings, Inc. | Dierks Jeffrey | Chief Commercial Officer | S - Sale+OE | $37.00 | -5,000 | 0 | -100% | -$185,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |